CILOSTAMIDE manufacturers
- Cilostamide
-
- $56.00
-
2026-07-14
- CAS:68550-75-4
- Purity: 98.87%
- Supply Ability: 10g
|
| | CILOSTAMIDE Basic information |
| Product Name: | CILOSTAMIDE | | Synonyms: | OPC 3689;OCP 3689;N-CYCLOHEXYL-N-METHYL-4-(1,2-DIHYDRO-2-OXO-6-QUINOLYLOXY)BUTYRAMIDE;CILOSTAMIDE;Cilostamide,OPC 3689;ciloalaMide;6-[3-(N-Cyclohexyl-N-methylcarbamoyl)propoxy]quinolin-2[1H]-one;N-cyclohexyl-4-[(2-hydroxyquinolin-6-yl)oxy]-N-methylbutanamide | | CAS: | 68550-75-4 | | MF: | C20H26N2O3 | | MW: | 342.43 | | EINECS: | | | Product Categories: | Cyclic Nucleotide related | | Mol File: | 68550-75-4.mol |  |
| | CILOSTAMIDE Chemical Properties |
| Melting point | 186～188℃ | | Boiling point | 594.3±50.0 °C(Predicted) | | density | 1.18±0.1 g/cm3(Predicted) | | storage temp. | 0-6°C | | solubility | Soluble in DMSO (up to 30 mg/ml). | | form | White solid | | pka | 11.12±0.70(Predicted) | | color | White | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. | | Cosmetics Ingredients Functions | SKIN PROTECTING | | InChI | 1S/C20H26N2O3/c1-22(16-6-3-2-4-7-16)20(24)8-5-13-25-17-10-11-18-15(14-17)9-12-19(23)21-18/h9-12,14,16H,2-8,13H2,1H3,(H,21,23) | | InChIKey | UIAYVIIHMORPSJ-UHFFFAOYSA-N | | SMILES | [nH]1c2c(cc[c]1=O)cc(cc2)OCCCC(=O)N(C3CCCCC3)C |
| RIDADR | 3249 | | WGK Germany | 3 | | HazardClass | 6.1(b) | | PackingGroup | III | | Storage Class | 11 - Combustible Solids |
| | CILOSTAMIDE Usage And Synthesis |
| Description | Cilostamide (68550-75-4) is a selective inhibitor of phosphodiesterase-3 (PDE3). Displays limited selectivity for PDE3A versus PDE3B (IC50 = 27 and 50 nM).1,2 Blocks PKB/Akt signaling pathway downstream via inhibition of Akt-activated PDE3B.3 Cilostamide reverses the effect of leptin on food intake and body weight.4 | | Uses | Serotonin receptor ligand | | Uses | Cilostamide (OPC 3689) is a specific phosphodiesterase 3 (PDE3) inhibitor. | | Definition | ChEBI: N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide is a member of quinolines. | | Biological Activity | Selective inhibitor of type III phosphodiesterase (PDE3). Displays moderate selectivity for PDE3A isozyme vs. PDE3B (IC 50 values are 0.027 and 0.050 μ M for PDE3A and PDE3B respectively). Inhibits ADP-induced platelet aggregation (IC 50 = 16.8 μ M); anti-thrombotic. Also available as part of the Phosphodiesterase Inhibitor Tocriset™ . | | Biochem/physiol Actions | Selective inhibitor of PDE3 (cGMP-inhibited phosphodiesterase); IC50 = 70 ± 9 nM. This inhibitory effect increases intracellular cAMP and inhibits platelet aggregation. | | storage | Store at RT | | References | [1] H HIDAKA. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.[J]. Journal of Pharmacology and Experimental Therapeutics, 1979, 211 1: 26-30.
[2] S. CHRISTENSEN T T. Chapter 19. Isozyme-Selective Phosphodiesterase Inhibitors as Antiasthmatic Agents[J]. Annual Reports in Medicinal Chemistry, 1994, 29 1: 185-194. DOI:10.1016/s0065-7743(08)60732-0
[3] F AHMAD. Cyclic nucleotide phosphodiesterase 3B is a downstream target of protein kinase B and may be involved in regulation of effects of protein kinase B on thymidine incorporation in FDCP2 cells.[J]. Journal of immunology, 2000, 164 9: 4678-4688. DOI:10.4049/jimmunol.164.9.4678
[4] ALLAN Z. ZHAO. A phosphatidylinositol 3-kinase–phosphodiesterase 3B–cyclic AMP pathway in hypothalamic action of leptin on feeding[J]. Nature neuroscience, 2002, 5 8: 727-728. DOI:10.1038/nn885 |
| | CILOSTAMIDE Preparation Products And Raw materials |
|